Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category


Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

 

UPDATED on 10/18/2017

Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

— Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time —

CAR T therapy is a breakthrough in hematologic cancer treatment in which a patient’s own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.

“The FDA approval of Yescarta is a landmark for patients with relapsed or refractory large B-cell lymphoma. This approval would not have been possible without the courageous commitment of patients and clinicians, as well as the ongoing dedication of Kite’s employees,” said Arie Belldegrun, MD, FACS, Founder of Kite. “We must also recognize the FDA for their ability to embrace and support transformational new technologies that treat life-threatening illnesses. We believe this is only the beginning for CAR T therapies.”

“Today is an important day for patients with relapsed or refractory large B-cell lymphoma who have run out of options and have been waiting for new treatments that may help them in their fight against cancer,” said John Milligan, PhD, President and Chief Executive Officer of Gilead Sciences. “With the combined innovation, talent and drive of the Kite and Gilead teams, we will rapidly advance cell therapy research and aim to bring new options to patients with many other types of cancer.”

The list price of Yescarta in the United States is $373,000.

Yescarta has been granted Priority Medicines (PRIME) regulatory support for DLBCL in the European Union. A Marketing Authorization Application (MAA) for axicabtagene ciloleucel is currently under review with the European Medicines Agency (EMA) and potential approval is expected in the first half of 2018.

Yescarta (axicabtagene ciloleucel) Pivotal Trial Results

The approval of Yescarta is supported by data from the ZUMA-1 pivotal trial. In this study, 72 percent of patients treated with a single infusion of Yescarta (n=101) responded to therapy (overall response rate) including 51 percent of patients who had no detectable cancer remaining (complete remission; 95% CI: 41, 62). At a median follow-up of 7.9 months, patients who had achieved a complete remission had not reached the estimated median duration of response (95% CI: 8.1 months, not estimable [NE]).

In the study, 13 percent of patients experienced grade 3 or higher cytokine release syndrome (CRS) and 31 percent experienced neurologic toxicities. The most common (≥ 10%) Grade 3 or higher reactions include febrile neutropenia, fever, CRS, encephalopathy, infections-pathogen unspecified, hypotension, hypoxia and lung infections. Serious adverse reactions occurred in 52% of patients and included CRS, neurologic toxicity, prolonged cytopenias (including neutropenia, thrombocytopenia and anemia), and serious infections. Fatal cases of CRS and neurologic toxicity occurred. FDA approved Yescarta with a Risk Evaluation and Mitigation Strategy.

Yescarta Indication

Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), accounting for three out of every five cases. In the United States each year, there are approximately 7,500 patients with refractory DLBCL who are eligible for CAR T therapy. Historically, when treated with the current standard of care, patients with refractory large B-cell lymphoma had a median overall survival of approximately six months, with only seven percent attaining a complete response. Currently, patients with large B-cell lymphoma in second or later lines of therapy have poor outcomes and greater unmet need, since nearly half of them either do not respond or relapse shortly after transplant.

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. “Many of the patients that received CAR T therapy had already relapsed several times with traditional treatments such as chemotherapy or hematopoietic stem cell transplant. Now, thanks to this new therapy many patients are in remission for months.”

“This therapy is a new option for patients with relapsed or refractory large B-cell lymphoma who have run out of treatment options and face a dire prognosis,” said Louis J. DeGennaro, PhD, President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS). “Early on, LLS recognized the potential of CAR T therapy and we are proud to be part of making this historic approval possible.”

“Engineered cell therapies like Yescarta represent the potential for a changing treatment paradigm for cancer patients,” said David Chang, MD, PhD, Worldwide Head of Research and Development and Chief Medical Officer at Kite. “Together, Gilead and Kite will accelerate studies of CAR T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors, with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

http://www.businesswire.com/news/home/20171018006639/en/Kite%E2%80%99s-Yescarta%E2%84%A2-Axicabtagene-Ciloleucel-CAR-Therapy-Approved

This article has the following structure:

  • ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)
  • ABOUT Gilead’s $12 billion buy of Kite Pharma
  • ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes
  • ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes
  • ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel
  • Key Opinion Leader’s View: Aviva Lev-Ari, PhD, RN

 

  1. I agree with Prof. Zelig Eshhar that this Case in Point is “one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.”
  2. I agree with Prof. Zelig Eshhar that this Case in Point should have been a TEVA commercialization effort. It is a regrettable reality that the development and the manufacturing will not benefit the State of Israel, home of the Weitzman Institute where the Patentable invention took place by Prof. Zelig Eshhar.
  3. It is to be acknowledged that for CAR-T – the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry (Juno has related process) – is bringing to the Oncology arena a NOVEL treatment for hematological malignancies cancer patients
  4. I agree with Prof. Zelig Eshhar that the Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. It is exactly, therefore, all need to acknowledge that the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun is inseparable from the breakthrough invention of Prof. Zelig Eshhar to develop the drug from the Lab bench to the FDA accelerated process of Drug approval.
  5. The Biotech industry in Israel needs to develop more MDs, PhDs with the level of training of Arie Belldegrun and with his entrepreneur acumen, keenness and depth of perception, discernmentdiscrimination especially in practical aspects of Translation Medicine, Clinical Research, Clinical Trial Design and abilities to engage in innovating the FDA processes.
  6. The Biotech industry in US needs to develop more MDs, PhDs with the level of training of Prof. Zelig Eshhar to carry the scientific gravitas and the creativity to become inventors of novel drugs.

 

ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)

Pioneers of Cancer Cell Therapy:  Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/08/19/pioneers-of-cancer-cell-therapy-turbocharging-the-immune-system-to-battle-cancer-cells-success-in-hematological-cancers-vs-solid-tumors/

 

ABOUT Gilead’s $12 billion buy of Kite Pharma

FDA has approved the world’s first CAR-T therapy, Novartis for Kymriah (tisagenlecleucel) and Gilead’s $12 billion buy of Kite Pharma, no approved drug and Canakinumab for Lung Cancer (may be?)

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/08/30/fda-has-approved-the-worlds-first-car-t-therapy-novartis-for-kymriah-tisagenlecleucel-and-gileads-12-billion-buy-of-kite-pharma-no-approved-drug-and-canakinumab-for-lung-cancer-may-be/

 

ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes

“Chemotherapy will become just a bad memory”

More energetic than ever, Arie Belldegrun talks to “Globes” about Kite Pharma’s remarkable journey and the future of cancer treatment.

http://www.globes.co.il/en/article-chemotherapy-will-become-just-a-bad-memory-1001206978

 

ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes

Kite Pharma was a $12b missed opportunity for Israel – Interview with Professor Zelig Eshhar

Some Israeli media headlines depicted Kite as an Israeli exit. But it is a US company that does no business in Israel and has no employees here.

Professor Zelig Eshhar is the man who registered the patent on the cancer treatment drug developed by Kite Pharma, recently acquired by Gilead for $11.9 billion.

“Globes”: Do you believe that any party in Israel could have financed the product and brought it where it is today?

Eshhar: “On the one hand, yes. The level of investment in the product before it reached Nasdaq was something that an Israeli concern could certainly have financed. On the other hand, Kite Pharma founder Professor Arie Belldegrun, with his energy and connections, brought it to a completely different place (Eshhar previously tried to interest various concerns in Israel in financing the drug, but all of them told him that it was too early, or that the product was not effective enough, E.T.).

Was the development already in its final form in the 1980s?

“Almost. I went to the National Institutes of Health (NIH), where I met for the first time Professor Steven Rosenberg, who later became the first doctor to conduct clinical trials with the technology. Rosenberg heard about my technology, and offered me exceptional conditions. We set up a team there, and had the best of everything. I only wish I had it now.”

They say that Belldegrun didn’t want the product at first. Today, he’s devoting all his efforts to it.

“When Arie founded Cougar Biotechnology, which developed a drug for prostate cancer, and was eventually sold to Johnson & Johnson for $1 billion, I contacted him and offered him the technology, but he was busy with Cougar’s product, and maybe didn’t think that he had enough capital for such a production. Only after he sold Cougar did he get back to me with an offer to buy the rights to my patent. At that time (2009-2010), the technology was already arousing great interest, and there were negotiations with several large companies.” (from an April 2015 “Globes” interview with Eshhar, who was awarded the Israel Prize).

Israelis can be very provincial. In at least some of the media headlines, Kite Pharma was portrayed as a “huge Israeli exit,” and the impression was given that it was an Israeli company. The truth is very different. Kite Pharma is not an Israeli company; it is a 100% US company. It does no business in Israel; its nearly $12 billion exit has no significance whatsoever for the Israeli economy, and will contribute nothing to it: no jobs, and the tax contribution will be marginal, and certainly not on the scale of Mobileye, for example. Let me say it again: Kite Pharma does not have even one employee in Israel (and has no reason to employ anyone here), and certainly does not pay taxes in Israel. There are no Israelis on the company’s management team or board of directors. This is a US company for all intents and purposes. The word “Israel” appears exactly once in the company’s full documents – where registration of the company’s patents is concerned. The fact that every story about the company mentions the small holdings of several Israeli financial institutions in it is a bad joke. Everyone should remember that Israeli financial institutions are of course entitled to invest in any foreign share, such as Google, Amazon, Facebook, Apple Computers, and so forth. Kite Pharma is one of those foreign shares, and nothing more.

Of course, there is cause for pride in the fact that Eshhar, owner of the patent for Kite Pharma’s drug is “one of ours,” i.e. an Israeli researcher at the Weizmann Institute of Science. Another source of pride is Kite Pharma founder and CEO Arie Belldegrun, a graduate of the Hebrew University Medical School who did his post-doctorate at the Weizmann Institute, where he met Eshhar, and Kite Pharma later bought his patent for the cancer drug. Belldegrun was also a director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) until recently, resigning at the peak of that company’s crisis. Beyond this Israeli connection, however, the Kite Pharma exit has no great significance for Israel. All it means is that one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.

It is necessary to realize that while Belldegrun is indeed a big biomedical brain with many achievements in the field, he is a brain that has left Israel, and we all have to ask ourselves why he left, why Kite Pharma is not an Israeli company, and why its (as yet non-existent) product was not developed in Israel and will not be manufactured there. The headline in Israel for the Kite Pharma exit should ask why Israel lost out on it, even though the patent came from Israeli laboratories, albeit with US cooperation.

Belldegrun is likely to keep his experiences on the Teva board of directors to himself. Of all the directors in the company, what he has to say is the most interesting, but he is unlikely to divulge what happened there with the inflated deal with Allergan, and exactly what he said at the board of directors meeting that approved the deal that led Teva into its current major crisis. The Kite Pharma exit and his other exits only highlight the lost opportunity. Kite Pharma, still without a product and without approval for a product, was sold for $11.9 billion in cash. Teva yesterday hit another low point, with a market cap of $16 billion. It is simply inconceivable: a company with an enormous potential, but no product, is worth three quarters of a huge veteran company with at least dozens of products, including products in the ethical drug sector. Kite Pharma is actually one of the indirect reasons for Teva’s decline – for the fact that Teva, which could have been a hothouse for developments like Copaxone, chose a huge inflated gamble on the generics market – a gamble that is now jeopardizing Teva’s future and very existence.

It is true that developing drugs is a very long process, requires huge amounts of capital, and involves many failures, but Teva decided to neglect it, and when a major company like Teva neglects Israeli developments, there are enough competitors in the pharma industry ready to turn Israeli research into gold. Kite Pharma is one example of this research.

The Weizmann Institute is a fruitful source of biomedical research. According to previous estimates published in “Globes,” the Weizmann Institute gets NIS 1 billion each year in royalties on medical and other developments, amounting to half of its budget. Directly and indirectly, the Weizmann Institute, together with other universities in Israel, is responsible for tens of billions of pharmaceutical sales. Only a few billions of this, however, results from drugs developed in Israel, like Copaxone, and far less than that is also made in Israel. The reports by Yeda R&D Company Ltd., the technology transfer arm of the Weizmann Institute of Science, are top secret, and there is a good reason for that. Exposing them will only highlight the scale of the missed opportunities. Instead of these inventions providing a base for a major pharmaceutical industry here, the commercialization companies are benefiting only the inventors and the Weizmann Institute itself (that is certainly natural and legitimate, and they are entitled to it), even though the research infrastructure from which they sprung is Israeli know-how, as in the case of Eshhar.

Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. When it succeeds, however, the profit is enormous – for the industry, the employees, and the state (provided that some tax is paid). For example, Pfizer’s peak sales of Lipitor, a very popular drug for reducing cholesterol and fat in the bloodstream, reached $11 billion, and its profit on the drug was $9 billion, before competition from a generic version began. In addition to money, a great deal of experience and marketing power is required, and that is the reason why most developments wind up in the hands of major companies like Pfizer, Merck, and others at some stage. After all these qualifying statements, everyone who celebrated Kite Pharma’s exit should weep over it – it is another part of the sale of Israeli know-how overseas for a mess of pottage. Instead of consolidating a splendid pharma industry here, Israel is selling the brains with their know-how to foreigners. More than anything else, Teva’s decline and the Kite Pharma exit epitomize this sad and dangerous trend.

Published by Globes [online], Israel Business News – www.globes-online.com – on August 30, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-kite-pharma-the-huge-exit-that-israel-missed-1001203173

 

ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel

Israeli investors profit from $11.9b Kite acquisition

Pontifax fund and Israeli institutional investors will profit from the US personalized cancer drug company’s huge sale.  Part of the technology was developed at the Weizmann Institute

Pharmaceutical company Gilead Sciences Inc. has announced that it will acquire US company Kite Pharma Inc., developer of personalized cancer treatment drugs, at a company value of $11.9 billion. This is one of the biggest ever acquisitions of a company whose products have not yet been approved for marketing. The company value for the acquisition reflects a 29% premium on the market price.

Kite Pharma has developed a new method for genetically engineering immune system cells, so that they will make a focused attack on the malignant tumor. The company was founded in the US by Israeli-American Professor Arie Belldegrun, who already has two exits to his credit. He is also a former director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) (whose current value is not much more than the value at which Kite Pharma, a company with no products approved for marketing yet, is being acquired).

A significant part of the technology on which the product is based was developed by Professor Zelig Eshhar of the Weizmann Institute of Science.

The main Israeli beneficiary of the acquisition is the Pontifax fund, which invested $3.8 million in Kite Pharma at an early stage, but which distributed Kite Pharma shares worth $120 million to its investors. Among the investors in Pontifax that received shares in Kite Pharma are Menorah Mivtachim Holdings Ltd. (TASE: MORA) (which also bought shares on the market, and whose stake in the company is now worth over $100 million), The Phoenix Holdings Ltd. (TASE: PHOE1;PHOE5), Altshuler Shaham Ltd.Meitav Dash Investments Ltd. (TASE:MTDS), Harel Insurance Investments and Financial Services Ltd. (TASE: HARL), and Mori Arkin.

Kite Pharma is waiting for marketing approval of its first product, following a successful trial on 100 patients on a very abbreviated track for innovative cancer products. The product was initially designed for treatment of blood cancer, but it is now hoped that its use can later be expanded to treatment of other types of cancer. Gilead is making a big gamble, first of all that the US Food and Drug Administration (FDA) will fulfill its commitment to approve the product, even though the development plan it devised, together with the company, was very short and limited. The second gamble involves the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry.

Speaking about the talks to sell Kite, Prof. Arie Belldegrun told “Globes.” “We handled like in the IDF 669 unit. Nobody knew anything. Nobody heard anything. We held meetings in places where nobody would see us. And before we announced it only five employees knew about it.”

Published by Globes [online], Israel Business News – www.globes-online.com – on August 28, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-israeli-investors-profit-from-119b-kite-acquisition-1001202841

 

Other related articles published in this Open Access Online Scientific Journal include the following: 

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2) – on Amazon since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

Advertisements

Read Full Post »


LIVE HubWeek – Harvard, MIT, MGH, Boston multiple locations, 10/10 – 10/15, 2017

Reporter: Aviva Lev-Ari, PhD, RN

 

I attended several events on THU, October 12, 2017

DEEP DIVE: The AI Revolution in Medicine

9AM — 11:30AM Faneuil Hall

Panelists:

Jayashree Kalpathy-Cramer, PhD, co-director of the Quantitative Tumor Imaging at Martinos (QTIM) Lab at the A.A. Martinos Center for Biomedical Imaging at MGH

Tina Kapur, PhD, executive director of Image Guided Therapy, Department of Radiology, BWH

Katherine P. Andriole, PhD, FSIIM, director of Research Strategy and Operations, MGH and BWH Center for Clinical Data Science

Dina Katabi, PhD, Andrew & Erna Viterbi Professor of EE and CS at MIT, director of MIT Center for Wireless Networks and Mobile Computing

10:30 – 11:00AM: Generating data and other AI challenges

Highlights

  • Dina Katabi, PhD – presented 21st Century technologies under development at MIT
  • Katherine P. Andriole, PhD described innovations in EMR

Voices of Oncology Discovery – Presented by HMS Executive Education

Red Dome, 1:30-3PM

  • Thomas Lynch Jr., MD, Executive VP, CSO, BMS
  • Alice Shaw, MD, PhD, Paula O’Keeffe Endowed Chair of Thoracis Oncology, MGH, Associate Professor of Medicine, HMS
  • Arlene Sharpe, PhD, George Fabyan Prof. of Comparative Pathology, Co-Director Evergrande Center for Immunologic Disease, HMS
  • Linnea Olson, Artist, blogger, advocate and long-term cancer survivor
  • Stanley Y Shaw, MD, PhD, Associate Dean for Executive Education, HMS

Highlights

  • Success reported with targeted therapies, biomarkers facilitate Clinical Trial design provide benefits for translation to approval of therapies
  • Biomarkers enable to achieve enriched population in Clinical Trials
  • Genomics vs Tissue Agnostics – FDA approved a drug based on genomics ALONE
  • FDA – has a new directive requiring feedback from Patients
  • KRAS Mutation – no targeted therapy in existance yet
  • Targeted therapies are available for: EDFR, PD-L!, PD-L2, ALK
  • Price of Durg and Value to Patients: Impact on Big Pharma
  • Combination drug therapy is KING
  • Data analytics, Urgency for response to drugs, clinical trials have accelerated path to approval if no alternative on the market

VOICE of the Cancer survival patient:

  1. Don’t give up
  2. Patient must have a seat at the Table
  3. Cancer as chronic disease while a search for cure continues

The Personalized Cell Therapy Challenge: A Race against Time

Green Dome, 4:00PM – 5PM

Udit Batra, Dr. Shashi Murthy, David Williams, Bruce Levine, Goeff Hodge

 

Healthy Brain, Enlightened Brain

Faneuil Hall, 5;30PM – 7PM

Deepak Chopra, MD and Dr. Rudy Tanzi, Reverend Liz Walker

Highlights

  • Importance of Sleep

Health Buzz: Why How Much You Sleep Could Affect Your Risk for Alzheimer’s Disease

  • Importance od De-Stress Methods
  • Nutrition and Microbiome
  • Early detection of AD – 20 years before onset of symptomes

Book signing:

MGH- Institute for Brain Health

Jonathan Rosand, MD
Dr. Jonathan Rosand is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology at Harvard, the J. P. Kistler Chair in Neurology, and Neurologist at Massachusetts General Hospital where he is Chief of the Division of Neurocritical Care and Emergency Neurology. A clinician-scientist with expertise in prevention of cerebrovascular diseases and preservation of brain function following stroke and brain injury, he brings the most advanced techniques of personalized medicine to his practice. In his laboratory within the Mass General Center for Human Genetic Research, Dr. Rosand directs a world-class research program in genetics that continues to discover new genes that influence susceptibility to and recovery from stroke.

Rudolph Tanzi, PhD
Dr. Rudy Tanzi is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University, Vice-Chair of Neurology (Research) at MGH and Co-Chair of the Mass General Research Council. He received his Ph.D. in Neurobiology from Harvard University. The four new AD candidates discovered by the Alzheimer’s Genome Project, headed by Tanzi, were named as one of the ten top medical breakthroughs of 2008 by Time magazine. He has received the two highest awards in the field of AD research: The Metropolitan Life Award for Biomedical Research and the Potamkin Prize. Dr. Tanzi has co-authored over 450 research publications, and in 2012, co-authored the New York Times Best Selling book, “Super Brain”.

 

GO TO

https://hubweek.swoogo.com/tickets/begin?package_id=3184

Selection Price
The HUB Pass (FREE) $0.00
Designing Biology: New Paradigms for Collaboration
Oct 10, 2017, 10:30 AM – 12:15 PM
$0.00
How the Hub is Steering the Digital Health Revolution
Oct 10, 2017, 4:30 PM – 7:00 PM
$0.00
Total $0.00
Continue 
If you would like to register for more events, please select them below. If you have selected all the events that you would like to attend, please click “Continue” (You can always modify your schedule after you finish registering)

Choose your events:

Name Date & Time More Info
Leveraging Sustainable Design to Achieve Social Equity

Sold Out
Tuesday, October 10, 2017, 8:00 AM – 10:00 AM
The Organ Generation

Sold Out
Tuesday, October 10, 2017, 8:30 AM – 10:00 AM
Creating Connected Communities with Design Thinking–Ideation

Sold Out
Tuesday, October 10, 2017, 9:00 AM – 12:00 PM
Boston Landing Development Presentation Tuesday, October 10, 2017, 10:00 AM – 11:00 AM
Maximize Innovation with Universal Design Tuesday, October 10, 2017, 10:00 AM – 12:00 PM
Mobile @Scale Tuesday, October 10, 2017, 10:00 AM – 5:00 PM
Designing Biology: New Paradigms for Collaboration Tuesday, October 10, 2017, 10:30 AM – 12:15 PM
Fitness Class at Athlete’s Park Tuesday, October 10, 2017, 11:00 AM – 12:00 PM
Public Skate at the Warrior Ice Arena Tuesday, October 10, 2017, 12:00 PM – 3:00 PM
Women in Science Luncheon Tuesday, October 10, 2017, 12:00 PM – 2:00 PM
Programming the Future of AI: Ethics, Governance, and Justice

Sold Out
Tuesday, October 10, 2017, 12:00 PM – 1:00 PM
Salesforce Growth Camp Tuesday, October 10, 2017, 12:00 PM – 6:00 PM
Presentation Skills & Public Speaking Workshop

Sold Out
Tuesday, October 10, 2017, 12:45 PM – 2:15 PM
The Human Face of AI

Sold Out
Tuesday, October 10, 2017, 12:45 PM
Giza 3D: Visualizing the Pyramids

Sold Out
Tuesday, October 10, 2017, 1:00 PM – 2:00 PM
Ancient DNA: Mediterranean Pathogens and Mobility Tuesday, October 10, 2017, 2:00 PM – 5:00 PM
Building a Startup in Boston

Sold Out
Tuesday, October 10, 2017, 2:30 PM – 3:15 PM
The Art of Storytelling

Sold Out
Tuesday, October 10, 2017, 2:45 PM – 4:15 PM
Innovation at Boston Health Care for the Homeless Tuesday, October 10, 2017, 3:00 PM – 4:30 PM
Breaking Into Biotech

Sold Out
Tuesday, October 10, 2017, 3:30 PM – 5:00 PM
How AI Makes Us More Human

Sold Out
Tuesday, October 10, 2017, 4:00 PM – 5:00 PM
“Walk A Mile” Poverty Simulation Tuesday, October 10, 2017, 4:00 PM – 6:30 PM
How the Hub is Steering the Digital Health Revolution Tuesday, October 10, 2017, 4:30 PM – 7:00 PM
How To Connect With Anyone Tuesday, October 10, 2017, 4:45 PM – 6:15 PM
The Future of Robotics

Sold Out
Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Aging & Caregiving Digital Health Reverse Pitches Tuesday, October 10, 2017, 5:00 PM – 8:00 PM
The Neuroscience Behind Consumer Decision-Making Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Reducing & Managing Stress: Walking the Labyrinth Tuesday, October 10, 2017, 5:30 PM – 6:30 PM
Diversity in Business: How to Bring Meaningful Change Tuesday, October 10, 2017, 5:30 PM – 7:30 PM
Innovation in the Regional Food System Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
When the Best Idea Fails Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Activating Purpose in the Workplace Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
Venture Café Kendall Connect Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Open House at The Engine Tuesday, October 10, 2017, 6:00 PM
HUBweek Roxbury Innovation Showcase Tuesday, October 10, 2017, 6:00 PM – 9:00 PM
Hiring & Reskilling for the Future Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
Create, Engage & Change: Urbano Project Open Studio Tuesday, October 10, 2017, 6:30 PM – 9:30 PM
Are You Truly Connected? Tuesday, October 10, 2017, 6:30 PM – 9:00 PM
The Changing Boston Designscape Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
How To Be A Successful Networker Tuesday, October 10, 2017, 6:45 PM – 8:15 PM
The Science of 3D Knitting Tuesday, October 10, 2017, 7:45 PM
Finding Heaven Under Our Feet Tuesday, October 10, 2017, 8:00 PM – 9:45 PM
Behind The Scenes Of Successful Entrepreneurs Wednesday, October 11, 2017, 8:00 AM – 10:00 AM
Tour: Design Biennial Boston Wednesday, October 11, 2017, 8:30 AM – 9:30 AM
Engineering + Entrepreneurship: Innovation in Healthcare Wednesday, October 11, 2017, 9:00 AM – 3:00 PM
The Silk Road: Taking Breakthroughs Global Wednesday, October 11, 2017, 9:00 AM
Cancer Disparities + Diversity in Life Sciences Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
MIT Public Art and Architecture Tour (Morning)

Sold Out
Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
War on Cancer 3.0 Wednesday, October 11, 2017, 11:00 AM – 12:00 PM
Kendall Square: Innovation Playground Wednesday, October 11, 2017, 12:00 PM
How to Attract Global Entrepreneurs to Boston Wednesday, October 11, 2017, 12:00 PM – 1:00 PM
AAUW Work Smart in Boston Salary Negotiation Workshop I Wednesday, October 11, 2017, 12:00 PM – 2:00 PM
Free Yoga & Meditation Class Wednesday, October 11, 2017, 12:15 PM – 2:00 PM
Creating Connected Communities with Design Thinking–Rapid Prototyping Wednesday, October 11, 2017, 1:00 PM – 4:00 PM
Bully Boy Distillery Tour Wednesday, October 11, 2017, 1:30 PM – 3:30 PM
Art of Talking Science Competition: Rise of the Machines Wednesday, October 11, 2017, 2:00 PM – 4:00 PM
MIT Public Art and Architecture Tour (Afternoon)

Sold Out
Wednesday, October 11, 2017, 2:00 PM – 3:00 PM
The Harvard Yard Archaeology Project Wednesday, October 11, 2017, 2:30 PM – 3:30 PM
Inside the Brigham: Innovation in Action Wednesday, October 11, 2017, 3:00 PM – 6:00 PM
Marine Science Boston Harbor Cruise

Sold Out
Wednesday, October 11, 2017, 3:00 PM – 5:00 PM
5th Annual BUILD Entrepreneur Games Wednesday, October 11, 2017, 3:00 PM – 7:30 PM
Healthcare Redesign Collaborative Wednesday, October 11, 2017, 3:30 PM – 6:00 PM
Ramp-Up E-commerce Conversions Wednesday, October 11, 2017, 3:45 PM – 5:45 PM
Healthcare and the Experience Economy Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
Harvard Innovation Labs Startup Showcase and Stories Wednesday, October 11, 2017, 4:00 PM – 6:00 PM
Green Innovation Industry Night Wednesday, October 11, 2017, 4:00 PM – 8:00 PM
Decoding the Dynaymic Cyber Threat Landscape Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
IoT for Good: Connected, Inclusive, Smart Cities

Sold Out
Wednesday, October 11, 2017, 4:30 PM – 6:30 PM
Rare Rights. Common Cause. Wednesday, October 11, 2017, 4:45 PM
Dell PolicyHack Wednesday, October 11, 2017, 5:00 PM – 9:00 PM
The Female Entrepreneur’s Experience in Boston Wednesday, October 11, 2017, 5:00 PM – 7:00 PM
Love the Problem Showcase! Innovation That Solves Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
AAUW Work Smart in Boston Salary Negotiation Workshop II Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Fall Café Night: District Hall’s 4th Birthday Party Wednesday, October 11, 2017, 5:30 PM – 9:00 PM
Geometry As Public Art: The Immigrant Experience Wednesday, October 11, 2017, 5:30 PM – 6:30 PM
Artificial Intelligence (and More) in Healthcare Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Celebration of Student Entrepreneurship in Boston Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Two Lenses: Communicating Science Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Innovation, the New Foundation of Urban Living Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Twilight: Exploring the Unconscious Mind Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
The City Talks: STEAM Wednesday, October 11, 2017, 6:00 PM – 7:00 PM
Fact/Fiction: Driving Truth into Policy Debates Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Civic Series presents: Breaking Through Gridlock Wednesday, October 11, 2017, 6:00 PM – 8:30 PM
Runnin’: A circle of friends. An American epidemic. Wednesday, October 11, 2017, 6:30 PM – 8:00 PM
GlobeDocs: Opening Night Film–Bending the Arc Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Opening Night Film–Bending the Arc + Reception Wednesday, October 11, 2017, 7:00 PM – 11:00 PM
Environmental Film Festival: Happening – A Clean Energy Revolution Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
The City Talks: Art and Medicine Wednesday, October 11, 2017, 7:30 PM – 8:30 PM
Innovation Women Pop-up (Thursday) Thursday, October 12, 2017, 8:00 AM
Deep Dive: The A.I. Revolution in Medicine Thursday, October 12, 2017, 9:00 AM – 12:00 PM
What it Means to be Part of a Movement Thursday, October 12, 2017, 11:00 AM – 12:00 PM
Exploration Phase I (Thursday) Thursday, October 12, 2017, 12:00 PM – 1:00 PM
Swiss-Made: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 2:00 PM – 2:30 PM
Deep Dive: Voices of Oncology Thursday, October 12, 2017, 2:00 PM – 3:30 PM
Do We Trust Our Digital Economy? Thursday, October 12, 2017, 2:30 PM – 3:30 PM
Abstract Superconscious (Thursday) Thursday, October 12, 2017, 2:30 PM
SAT FEST 2017 (Thursday) Thursday, October 12, 2017, 3:00 PM – 3:45 PM
Uncharted Domain (Thursday) Thursday, October 12, 2017, 3:00 PM
Linked Threats: Climate Change and Social Inequality Thursday, October 12, 2017, 3:35 PM – 4:15 PM
Made in USA: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 3:45 PM – 4:45 PM
Social Justice and the New Food Activism Thursday, October 12, 2017, 4:00 PM – 5:30 PM
Investing in American Jobs Thursday, October 12, 2017, 4:15 PM – 5:00 PM
Fullscale Dome-ination (Thursday) Thursday, October 12, 2017, 4:30 PM – 5:00 PM
Future Forum: Thursday Night Session Thursday, October 12, 2017, 5:00 PM – 7:00 PM
Swiss-Made: Fulldome Immersive III (Thursday) Thursday, October 12, 2017, 5:00 PM – 5:30 PM
Swiss-Made: Fulldome Immersive IV (Thursday) Thursday, October 12, 2017, 5:30 PM – 6:00 PM
MIT IDE Inclusive Innovation Challenge Celebration Thursday, October 12, 2017, 6:00 PM – 7:30 PM
Immersion Artists Talk Series Thursday, October 12, 2017, 6:30 PM – 8:30 PM
LIVE Silent Disco Thursday, October 12, 2017, 7:00 PM – 10:00 PM
Exploration Phase II (Thursday) Thursday, October 12, 2017, 7:00 PM – 8:00 PM
Wasted! The Story of Food Waste Thursday, October 12, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Unrest Thursday, October 12, 2017, 7:30 PM – 9:30 PM
Live: Disorder 3D–Digital Choreography (Thursday) Thursday, October 12, 2017, 8:00 PM – 8:30 PM
Live: Disorder 3D–Digital Choreography (Friday) Thursday, October 12, 2017, 8:45 PM – 9:15 PM
Live: Disorder 3D–Digital Choreography (Saturday) Thursday, October 12, 2017, 9:30 PM – 10:00 PM
Innovation Women Pop-up (Friday) Friday, October 13, 2017, 8:00 AM
Deep Dive: Climate Change Friday, October 13, 2017, 9:00 AM – 12:00 PM
Swiss-Made: Fulldome Immersive I (Friday) Friday, October 13, 2017, 9:00 AM – 9:30 AM
Disrupting Poaching Networks Before They Kill Friday, October 13, 2017, 9:15 AM – 10:00 AM
Swiss-Made: Fulldome Immersive II (Friday) Friday, October 13, 2017, 9:30 AM – 10:00 AM
Made in USA: Fulldome Immersive II (Friday) Friday, October 13, 2017, 10:00 AM – 10:45 AM
Around Us. On Us. Within Us. Friday, October 13, 2017, 10:30 AM – 11:15 AM
Abstract Superconscious (Friday) Friday, October 13, 2017, 10:45 AM
Housing the Workforce:Typology Technology & Tectonics Friday, October 13, 2017, 11:05 AM – 11:55 AM
Initiative: The Women Behind Digital Health Friday, October 13, 2017, 12:00 PM – 1:15 PM
Exploration Phase I (Friday) Friday, October 13, 2017, 12:00 PM – 1:00 PM
Deep Dive: Innovations in Opioid Treatment and Recovery Friday, October 13, 2017, 1:00 PM – 4:00 PM
Swiss-Made: Fulldome Immersive III (Friday) Friday, October 13, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive IV (Friday) Friday, October 13, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Friday) Friday, October 13, 2017, 2:00 PM – 2:30 PM
Planetary Explorations (Friday) Friday, October 13, 2017, 2:30 PM – 3:00 PM
Leading for Creativity Friday, October 13, 2017, 3:50 PM – 4:30 PM
Stories Under the Stars (Friday) Friday, October 13, 2017, 4:00 PM
Friday Night Session: Saving As Many Lives As Penicillin

Sold Out
Friday, October 13, 2017, 5:00 PM – 7:00 PM
The Swiss Touch: Exploring Digital Utopia Friday, October 13, 2017, 5:00 PM – 7:00 PM
Beantown Throwdown Friday, October 13, 2017, 5:30 PM – 8:00 PM
Askwith Forum – Changes in Mind Friday, October 13, 2017, 5:30 PM – 7:00 PM
Coffee & Chocolate: Climate Change, Sustainability, and Gender Equity Friday, October 13, 2017, 6:00 PM – 8:30 PM
The Room Where It Happens: On the Agency of Interior Spaces (Keynote) Friday, October 13, 2017, 6:00 PM – 7:30 PM
Environmental Film Festival: Chasing Coral Friday, October 13, 2017, 6:30 PM – 9:00 PM
Unchained Brain Friday, October 13, 2017, 6:30 PM – 7:45 PM
Exploration Phase II (Friday) Friday, October 13, 2017, 7:00 PM – 8:00 PM
GlobeDocs: Human Flow Friday, October 13, 2017, 7:30 PM – 9:30 PM
On Point Live Friday, October 13, 2017, 7:30 PM – 9:00 PM
The Cypher Friday, October 13, 2017, 8:00 PM – 10:30 PM
SAT FEST 2017 (Friday) Friday, October 13, 2017, 8:45 PM – 9:30 PM
Fullscale Dome-ination (Friday) Friday, October 13, 2017, 9:30 PM – 10:00 PM
Planetary Explorations (Friday Night) Friday, October 13, 2017, 10:00 PM – 10:30 PM
Cosmic Meditation (Saturday) Saturday, October 14, 2017, 8:15 AM
The Room Where It Happens: On the Agency of Interior Spaces (Symposium) Saturday, October 14, 2017, 9:00 AM – 5:00 PM
Made in USA: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 9:30 AM – 10:15 AM
De-Stress Boston Saturday, October 14, 2017, 10:00 AM – 12:00 PM
Demo Day: Showcase Floor Saturday, October 14, 2017, 10:00 AM
Demo Day: Intro to Startups and Entrepreneurship in Boston Saturday, October 14, 2017, 10:00 AM – 10:50 AM
Intergalactic Yoga (Saturday) Saturday, October 14, 2017, 10:15 AM
Demo Day: Growing a Startup in Boston: Challenges and Advantages Saturday, October 14, 2017, 11:00 AM – 11:50 AM
Uncharted Domain (Saturday) Saturday, October 14, 2017, 11:30 AM
Demo Day: How to be an Ally in the Workplace Saturday, October 14, 2017, 12:00 PM – 12:50 PM
Exploration Phase I (Saturday) Saturday, October 14, 2017, 12:00 PM – 1:00 PM
GlobeDocs: Circle Up/Lenox Street Saturday, October 14, 2017, 12:00 PM – 2:00 PM
Demo Day: Founders Talking About Failure Saturday, October 14, 2017, 1:00 PM – 1:50 PM
Swiss-Made: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 1:30 PM – 2:00 PM
Abstract Superconscious (Saturday) Saturday, October 14, 2017, 2:00 PM
Demo Day: An Introduction to Funding Types Saturday, October 14, 2017, 2:00 PM – 2:50 PM
Swiss-Made: Fulldome Immersive III (Saturday) Saturday, October 14, 2017, 2:30 PM – 3:00 PM
GlobeDocs: Anatomy of a Male Ballet Dancer Saturday, October 14, 2017, 2:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive IV (Saturday) Saturday, October 14, 2017, 3:00 PM – 3:30 PM
Making a Live Storytelling Show for a Planetarium Saturday, October 14, 2017, 3:45 PM
Stories Under the Stars (Saturday) Saturday, October 14, 2017, 4:30 PM
GlobeDocs: Gladesmen – The Last of the Sawgrass Cowboys Saturday, October 14, 2017, 5:00 PM – 7:00 PM
Krip-Hop Nation: The Crossroads Experience Saturday, October 14, 2017, 5:00 PM – 6:00 PM
Made in USA: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 5:15 PM – 5:45 PM
SAT FEST 2017 (Saturday) Saturday, October 14, 2017, 5:45 PM – 6:30 PM
Demo Day: Finale Saturday, October 14, 2017, 6:00 PM – 8:00 PM
Fullscale Dome-ination (Saturday) Saturday, October 14, 2017, 6:30 PM – 7:00 PM
Exploration Phase II (Saturday) Saturday, October 14, 2017, 7:00 PM – 8:00 PM
WGBH: First Look: Bill Nye – Science Guy Saturday, October 14, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Jaha’s Promise Saturday, October 14, 2017, 7:30 PM – 9:30 PM
Pico Picante Saturday, October 14, 2017, 8:00 PM – 10:30 PM
Modulate Live–Dance Party Saturday, October 14, 2017, 9:15 PM – 10:45 PM
Intergalactic Yoga (Sunday) Sunday, October 15, 2017, 9:00 AM
Stories Under the Stars (Sunday) Sunday, October 15, 2017, 10:15 AM
Cosmic Meditation (Sunday) Sunday, October 15, 2017, 10:45 AM
Robot Block Party Sunday, October 15, 2017, 11:00 AM
GlobeDocs: Shorts Program–Changing Perspective Sunday, October 15, 2017, 11:30 AM – 1:30 PM
Green Up New England Challenge Sunday, October 15, 2017, 11:45 AM – 12:45 PM
Exploration Phase I (Sunday) Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Butterfly Effect: A Study in Prototyping, Art and Sustainability Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Design Museum: Digitally-Enabled Creativity Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Abstract Superconscious (Sunday) Sunday, October 15, 2017, 1:00 PM
A New Wave of Public Art in the Boston Area Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Made in USA: Fulldome Immersive I (Sunday) Sunday, October 15, 2017, 1:30 PM – 2:00 PM
Planetary Explorations (Saturday) Sunday, October 15, 2017, 2:00 PM – 2:30 PM
GlobeDocs: Hondros Sunday, October 15, 2017, 2:00 PM – 4:00 PM
Designing for Climate Change Sunday, October 15, 2017, 2:20 PM – 3:00 PM
Fullscale Dome-ination (Sunday) Sunday, October 15, 2017, 2:30 PM – 3:00 PM
Creative Placemaking – A View on Tactical Urbanism Sunday, October 15, 2017, 3:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive III (Sunday) Sunday, October 15, 2017, 3:30 PM – 4:00 PM
GlobeDocs: Quest Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: I Am Evidence Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: Closing Night Film–A Fine Line Sunday, October 15, 2017, 7:00 PM – 9:00 PM
WGBH: First Look: Frontline: Putin’s Revenge Sunday, October 15, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Closing Night Film–A Fine Line + Reception Sunday, October 15, 2017, 7:00 PM – 11:00 PM
Immersion Party 3-Pack

 

 

 

Read Full Post »


Success of the life sciences industry in Massachusetts: Governor Charlie Baker – A new 5 year, $500 million investment

Reporter: Aviva Lev-Ari, PhD, RN

 

We are thrilled to share this exciting news with you. Earlier today, Governor Charlie Baker announced he will be filing legislation to establish the next phase of the life sciences initiative with a new 5 year, $500 million investment. As the original 10-year, $1 billion program expires next year, this action is critical to the continued success of the life sciences industry in Massachusetts, and to patients around the world who continue to seek new treatments and cures they need and deserve.

As noted by the Governor’s office, the focus of this next phase of the life science initiative will include strengthening investments in human capital to fortify the state’s skilled workforce pipeline, expanding opportunities for companies to access both private investment capital and dynamic public infrastructure resources, developing new scientific innovations that deliver higher outcome, affordable therapies to patients, and leading the convergence revolution in digital health, biopharma, medical devices and engineering.

Over the last nine years the life science initiative and the Massachusetts Life Sciences Center has cemented Massachusetts as the life sciences leader nationally and across the world. In Cambridge and Boston we have the best, most dense biotech cluster in the world. In Worcester, we have a cluster which can stand on its own as one of the biggest in the country. And in the northern and southern parts of the state, jobs in the life sciences are growing faster than anywhere else in the state. With a $147,000 average salary, $9 billion in total payroll, and an expected 11,600 new jobs over the next five years, the life sciences is a huge economic engine for this state. With today’s announcement, we know that companies will continue to come and expand in Massachusetts for years to come and make our economy grow. 

Most importantly, the continuation of the life sciences initiative ensures that patients across the world will continue to receive the breakthrough cures and treatments that are being developed every day in Massachusetts. 

Today’s an exciting day for Massachusetts. We’re thrilled to be part of it.

– Bob Coughlin

 

SOURCE
From:
MassBio <communications@massbio.ccsend.com> on behalf of MassBio <robert.coughlin@massbio.org>

Reply-To: <communications@massbio.org>

Date: Monday, June 19, 2017 at 1:06 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Breaking News: Gov. Baker Announces Next Phase of Life Sciences Initiative

Read Full Post »


VC Investment in BioTech MegaHubs and Top R&D Spenders among Big Pharma

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 4/26/2017

The top 10 pharma R&D budgets in 2016

The Top 10 Pharma R&D Budgets in 2016

Read More:

SOURCE

http://www.fiercebiotech.com/special-report/top-10-pharma-r-d-budgets-2016?utm_medium=nl&utm_source=internal&mrkid=993697&mkt_tok=eyJpIjoiT1RSbE9ESTRNR1pqWTJFNCIsInQiOiJFcUx4MFhxSFVGbVZhUkRGdUdRMTJMUGxFSEkrR0VTMEdXbjRvZkxmdXM4em4wRkg5QXZIOWJJWTgwNHR1a1dVbTRIUFwvNWRIXC9ZTkF5dHlpUUZ4bG1lS2c2NkszQk9oeGtRczhLcnYyalRSZEFjOEl6U3dUY2VaakxUbDdkNGNwIn0%3D

Book traversal links for The top 10 pharma R&D budgets in 2016

 

 

 

Table SOURCE: Thomson Reuters abd ENDPOINTS

According to both sources:

  • $3.5 billion for Silicon Valley plus the Bay Area and
  • $2.8 billion for New England.

Broken down by city, $6.1 billion went to

  • Boston ($2.7 billion),
  • San Jose ($2.5 billion) and
  • San Francisco/Berkeley ($1 billion).
  • San Diego ($725 million),
  • New York ($454 million) and
  • the Great Lakes area ($412 million)

SOURCE

Where the money is: Biotech’s megahubs command VC’s billions by john carrollJune 30, 2016 10:41 AM EDT, Updated: November 17, 2016 07:32 PM

The top 15 spenders in the global drug R&D business: 2017

by john carroll

April 24, 2017 05:22 AM EDT, Updated: 05:27 AM

The top five in the business saw their collective spending jump by more than $5 billion, from 2015 to 2016, based on the annual numbers filed largely — though not entirely — with the SEC and gathered by Endpoints News. Two of those companies,

  • Roche and the new number 2, a hard charging
  • Merck, accounted for the lion’s share of the increase. (To be sure, some onetime non-R&D spending, such as Merck’s patent settlement with Bristol-Myers on Keytruda, figured in. But so did bread and butter spending.)
  • Gilead also saw a significant increase in research costs, with
  • Eli Lilly — now off course following two bad setbacks for solanezumab and baricitinib — and the ever aggressive
  • Celgene joining the action as they pressed the accelerator on new drug programs.

Curiously, the added spending coincided with a bad drop in new drug approvals in 2016. But they don’t correlate, and we’ve already seen that turnaround under way as regulators get busy with a brand new year — and soon a brand new FDA commissioner.

SOURCE

https://endpts.com/special/top-research-budgets-in-pharma-and-biotech/

Read Full Post »


Chan-Zuckerberg (CZ) Biohub Selects Researchers to Receive $50 Million to Fight Disease & consortium aimed at immunotherapy research

 

Reporter: Aviva Lev-Ari, PhD, RN

 

 

02/10/2017 – 4:33pm

 

Selecting the Candidates

It wasn’t easy to narrow down the applicant pool, according to Quake.

“Over 750 people submitted a three-page application proposing risky but innovative ideas. In return, we’d provide them with the funding to work on their ideas in an unrestricted capacity,” said Quake regarding the application process.

A panel comprised of 60 prominent engineers and scientists sifted through the applications that came from the three universities. Submissions came from a diverse array of departments, including computer science, engineering and mathematics before settling on the final 47 participants.

“It’s a phenomenal gathering of talent working on issues like using computer science to help understand human health through the use of wearables,” added Quake.

One notable member of this program is Jure Leskovec, Ph.D., who is a computer scientist at Stanford and the chief scientist at Pinterest. His work at the biohub will focus on using data to help biologists comprehend the interactions between the genes and proteins exposed to drugs or disease, according to Nature.

Other investigators include Ada Poon, Ph.D., hailing from Stanford who is studying new techniques for miniaturing bioelectronics devices, and Markita Landry, Ph.D., who is working on nanosensor technology and near infrared imaging platforms designed to visualize neurotransmitters in the brain.

The CZ Biohub will institute policies that enable quick dissemination of research papers through pre-print servers. This will help inform other researchers of their work and expedite the discovery process.

Next Steps

Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.

There are other research institutes forming in Silicon Valley, but with slightly different approaches. Sean Parker, the entrepreneur behind notorious music-sharing service Napster, launched a consortium aimed at immunotherapy research as well as a separate operation geared towards allergy research.

However, Quake said the Biohub concept appeals to a lot of researchers.

“There’s only a small number of faculty positions available each year and not everyone wants to teach, so we want the Biohub to be an alternate career path for researchers who love science,” he said.

http://www.rdmag.com/article/2017/02/chan-zuckerberg-biohub-selects-researchers-receive-50-million-fight-disease?et_cid=5825577&et_rid=461755519&type=cta&et_cid=5825577&et_rid=461755519&linkid=content

 

RELATED READS

Read Full Post »


We are seeking an independent public relations professional with extensive experience in the biotechnology/drug development sector to assist on a freelance basis to

  • promote an on line resource in drug development and personalized medicine in the global oncology sector. 

Responsibilities include working with agencies such as PR Newswire to distribute press releases prepared by us in house, and managing our proprietary mailing list and our social media accounts. 

Please, provide a detailed resume with contact information to knowledgebase@newmedinc.com.

 

Read Full Post »


Institutional Capital Raised by Female Founders in 2016 – A Global Perspective vs the US Economy: Globally 1,272 in the United States 600

Reporter: Aviva Lev-Ari, PhD, RN

2016 REVIEW OF FEMALE FOUNDERS RAISING INSTITUTIONAL CAPITAL

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

 

The Data Reflects Several Key Trends
Key Takeaways

Raising a Series A led by an institutional VC remains difficult, but female founders in NYC continued to be the most successful (compared to those in other cities) in 2016.
At 17%, the percentage of total A rounds led by female CEOs in 2016 represents the highest total percentage since Female Founders Fund started tracking the data in 2013.
In addition, New York saw a record number of Series B and C rounds led by female founders in 2016.
Female Founders Fund remains the most active institutional VC firm investing in early-stage female-led companies.
Funds that have traditionally been uninterested in e-commerce have renewed interest in the e-commerce sector following the Dollar Shave Club and Jet.com acquisitions by large strategic investors.

2016 Series A Rounds — NYC — Female CEO
Rockets of Awesome — $12.5 million — December — Rachel Blumenthal
Ellevest — $9.0 million — September — Sallie Krawcheck
CoheroHealth — $9.0 million — November — Melissa Manice
Away — $8.5 million — September — Steph Korey
Primary– $8.0 million — June — Galyn Bernard
goTenna — $7.5 million — March — Daniela Perdomo
LOLA — $7.0 million — December — Alex Friedman and Jordana Kier
Uncharted Play — $7.0 million — September — Jessica Matthews
Thrive Global — $7.0 million — August — Arianna Huffington
Everplans — $6.4 million — June — Abby Schneiderman
pymetrics — $6.1 million — February — Frida Polli
Sakara Life — $4.8 million — January — Whitney Tingle, Danielle DuBoise
Shoppable — $3.5 million — August — Heather Marie
MMLaFleur — Sarah LaFleur

2016 Series A Rounds — Bay Area — Female CEO

Cortexyme — $15.0 million — January — Casey Lynch
FOVE — $11.0 million — March — Yuka Kojima
Front — $10.0 million — May — Mathilde Collin
REBBL — $10.0 million — December — Sheryl O’Loughlin
Nima — $9.2 million — May — Shireen Yates
Rocksbox — $8.7 million — March — Meaghan Rose
LaunchDarkly — $8.7 million — December — Edith Harbaugh
Modsy — $8.0 million — February — Shanna Tellerman
ThirdLove — $8.0 million — February — Heidi Zak
Node — $7.5 million — June — Falon Fatemi
Shippo — $7.0 million — September — Laura Behrens Wu
Mobilize — $6.5 million — September — Sharon Savariego
Neurotrack — $6.5 million — January — Elli Kaplan
Sourcery — $5.0 million — September — Na’ama Moran
Luka — $4.4 million — April — Eugenia Kuyda
SupportPay — $4.1 million — December — Sheri Atwood
Zybooks — $4.0 million — February — Smita Bakshi
Schoola — $3.6 million — May — Stacey Boyd

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

 

 

Series A Rounds in 2016

Our 2016 analysis began with an overall review of Series A rounds globally, nationally and regionally.

2017 Research Graph 1

Series A Rounds Raised Globally, Nationally and Regionally in 2016

Series A Rounds in 2016:

 

 

 

2016 Series A Rounds in 2016:

Globally: 1,272
United States: 600
Bay Area: 187
NYC: 84
Boston: 31
Los Angeles: 38
Seattle: 26
Austin: 7
Washington D.C.: 17

2015 Series A Rounds in 2015:

Globally: 1,164

United States: 664

Bay Area: 205

NYC: 96

Boston: 50

Los Angeles: 40

Seattle: 25

Austin: 22

Washington D.C.: 17

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

The total number of Series A rounds in the U.S. decreased by 10% in 2016. Of the seven regions that we track in the U.S., Seattle is the only region that experienced an increase in the number of Series A raises in 2016, at 4%.

While overall Series A activity declined slightly in Los Angeles, there were two large Series A raises for female-led businesses — (i) HopSkipDrive, led by CEO Joanna McFarland, which raised $10.2 million in January 2016 from Upfront Ventures and FirstMark Capital; and (ii) Hutch, led by CEO Beatrice Fischel-Bock, which raised $5 million in July 2016 from Founders Fund. Los Angeles remains among the most female entrepreneur-friendly cities in the U.S.

 

VC’s investing in female-led companies in 2016.

Female Founders Fund remained the most active investor, participating in 3 of the 14 — or 21% — of all female-led A rounds in NYC. – See more at: http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

– See more at:

http://femalefoundersfund.com/2016-review-of-female-founders-raising-institutional-capital/#sthash.Pcuj7rVB.dpuf

Read Full Post »

Older Posts »